Imakrebin (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug stops the signaling pathways that drive uncontrolled cell growth, leading to reduced tumor proliferation and increased cancer cell death.

The exact dose of Imakrebin is determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Dosage adjustments are made individually and should follow the prescriber’s written instructions.

Safety data for imatinib in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the Imakrebin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imakrebin (imatinib) was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and Ph+ ALL. Newer agents such as dasatinib or nilotinib may offer potency against certain resistant mutations, but imatinib’s long‑term safety profile and extensive clinical experience make it a widely used first‑line option.

Imakrebin tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Imakrebin is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their healthcare provider regarding timing relative to meals.

Serious risks include hepatotoxicity, severe neutropenia, cardiac failure, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts and cardiac function, and any signs of severe adverse reactions should prompt immediate medical evaluation.

Imakrebin is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised in individuals with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those who are pregnant without a clear benefit‑risk assessment.